A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of D. Ryan Ormond

D. Ryan Ormond

Study ID

Protocol Number: 24-0020

More information available at ClinicalTrials.gov: NCT05484622

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers